Double/Triple Hit Lymphoma (HGBL-MYC/BCL2/BCL6) — Expert Treatment

Double-hit lymphoma (DHL) is a specific subtype of high-grade B-cell lymphoma defined by the co-occurrence of chromosomal rearrangements involving both MYC (which drives cell proliferation) and BCL2 or BCL6 (which prevents cell death or promotes aberrant survival). This combination creates a particularly aggressive cancer because tumor cells simultaneously proliferate rapidly and resist the normal signals that should cause them to die. Standard DLBCL chemotherapy (R-CHOP) produces substantially inferior outcomes in DHL compared to regular DLBCL, which is why more intensive treatment regimens -- particularly DA-R-EPOCH -- are used at expert lymphoma centers.

Double-hit lymphoma (DHL) is defined by chromosomal rearrangements of MYC and BCL2 or BCL6, detectable only by FISH testing. Double-expressor lymphoma (DEL) refers to high MYC and BCL2 protein levels detected by standard immunohistochemistry (IHC) -- without the underlying chromosomal rearrangements. DEL carries a worse prognosis than standard DLBCL but better than true DHL. Critically, a patient can have DEL by IHC without having DHL by FISH. This is why FISH testing for MYC, BCL2, and BCL6 is essential for all newly diagnosed large B-cell lymphomas -- IHC alone is not sufficient to determine whether a patient has DHL.

FISH (fluorescence in-situ hybridization) testing identifies chromosomal rearrangements at the DNA level, which is the only way to definitively diagnose double-hit or triple-hit lymphoma. Standard pathology including immunohistochemistry can raise suspicion -- particularly when both MYC and BCL2 proteins are overexpressed -- but cannot confirm or exclude DHL without FISH. Since DHL requires a different (more intensive) treatment regimen than standard DLBCL, missing the diagnosis means a patient may be undertreated with R-CHOP when they need DA-R-EPOCH. FISH testing should be performed on all newly diagnosed aggressive large B-cell lymphomas.

R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) is the standard first-line treatment for typical DLBCL and produces good outcomes in that context. However, in DHL/THL, multiple retrospective analyses have consistently shown that R-CHOP produces significantly lower complete response rates and worse overall survival compared to more intensive regimens. This is believed to reflect the heightened resistance to apoptosis conferred by BCL2 overexpression and the extreme proliferative drive from MYC, which requires more intensive chemotherapy exposure to achieve disease control. DA-R-EPOCH (dose-adjusted rituximab-EPOCH) is the preferred alternative at most specialist lymphoma centers.

DA-R-EPOCH (dose-adjusted rituximab etoposide prednisone vincristine cyclophosphamide doxorubicin) uses 96-hour continuous infusions of etoposide, vincristine, and doxorubicin -- rather than the bolus injections used in R-CHOP -- combined with cyclophosphamide and prednisone given on day 5, with rituximab on day 1. The extended infusion duration exposes cells to drug throughout the cell cycle, which is particularly important for rapidly cycling MYC-driven DHL cells. Doses are adjusted upward with each subsequent cycle based on the depth of neutropenia achieved, ensuring maximum intensity. DA-R-EPOCH is significantly more intensive than R-CHOP and requires a central venous catheter and careful monitoring.

Patients with DHL/THL have a substantially elevated risk of central nervous system (CNS) relapse compared to standard DLBCL -- estimated at 10-25% or higher in the highest-risk groups. CNS relapse is devastating because it is typically rapidly progressive and very difficult to treat effectively once established. CNS prophylaxis -- which can involve intrathecal (spinal fluid) chemotherapy injections with each cycle, high-dose IV methotrexate (which penetrates the blood-brain barrier), or CNS coverage inherent in certain regimens -- aims to eliminate any microscopic CNS disease and prevent CNS relapse. A baseline lumbar puncture (spinal tap) to check the cerebrospinal fluid for lymphoma cells is recommended at diagnosis.

CAR-T cell therapy (chimeric antigen receptor T-cell therapy) involves collecting a patient's own T-cells, genetically engineering them in the laboratory to recognize and attack CD19 on B-lymphoma cells, and infusing them back into the patient. For relapsed/refractory large B-cell lymphoma including DHL/THL after two or more prior lines of treatment, three CAR-T products are FDA-approved: axicabtagene ciloleucel (Yescarta), tisagenlecleucel (Kymriah), and lisocabtagene maraleucel (Breyanzi). Axicabtagene ciloleucel is also approved after just one prior line of therapy for primary refractory large B-cell lymphoma. CAR-T represents one of the most important treatment options for relapsed DHL/THL and is available at specialist CAR-T certified centers in India and internationally.

Venetoclax is a BCL2 inhibitor that works by blocking BCL2's anti-apoptotic function -- the same mechanism that contributes to DHL/THL aggressiveness in BCL2-rearranged cases. This biological rationale has made venetoclax-based combinations in MYC+BCL2 DHL an active area of clinical investigation. Several ongoing trials are evaluating venetoclax added to DA-R-EPOCH or other chemotherapy backbones specifically in BCL2-rearranged DHL. While venetoclax is not yet approved as standard treatment for DHL/THL, it represents a highly rational therapeutic target and patients with BCL2-rearranged DHL should discuss clinical trial eligibility with their lymphoma specialist.

Yes. CancerFax connects patients with double-hit and triple-hit lymphoma to specialist lymphoma hematologists for FISH result interpretation, confirmation of diagnosis, treatment protocol selection (DA-R-EPOCH vs alternatives), CNS prophylaxis planning, and access to clinical trials evaluating venetoclax combinations, bispecific antibodies, and novel MYC and BCL6-targeted approaches. For relapsed/refractory disease, CancerFax facilitates CAR-T eligibility assessment and coordination with certified CAR-T centers in India, the United States, Europe, and China, as well as access to next-generation bispecific antibody therapies and investigational agents.